hVIVO plc Award of Share Options (9210B)
January 16 2018 - 1:00AM
UK Regulatory
TIDMHVO
RNS Number : 9210B
hVIVO plc
16 January 2018
For immediate release 7.00am: 16 January 2018
HVIVO PLC
("hVIVO" or the "Company")
Award of Share Options
hVIVO plc (AIM: HVO), a specialty biopharma company with
discovery and clinical testing capabilities, announces that on 15
January 2018 it awarded the following options over ordinary shares
of 5.0p each in the Company to Liam Eves:
Name Position Number Exercise Date of Percentage
of Share price Vesting of issued
Options per ordinary
Awarded Share share
capital
----------- ------------------ ---------- --------- ------------ -----------
Executive
Vice President, 20 December
Liam Eves Humatics 136,364 5.0p 2020 0.17%
----------- ------------------ ---------- --------- ------------ -----------
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the persons discharging managerial
responsibilities/persons closely associated
--- -------------------------------------------------------
a) Name Liam Eves
--- ----------------- ------------------------------------
2 Reason for the notification
--- -------------------------------------------------------
a) Position/ Executive Vice President, Humatics
status - A person closely associated
with Kym Denny, Chief Executive
Officer of the Company
--- ----------------- ------------------------------------
b) Initial Initial Notification
notification/
Amendment
--- ----------------- ------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- -------------------------------------------------------
a) Name hVIVO plc
--- ----------------- ------------------------------------
b) Legal Entity N/A
Identifier
--- ----------------- ------------------------------------
4 Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- -------------------------------------------------------
a) Description Options over Ordinary Shares of
of the 5 pence each
financial
instrument,
type of ISIN: GB00B6ZM0X53
instrument
Identification
code
--- ----------------- ------------------------------------
b) Nature Award of options over Ordinary
of the Shares in the Company
transaction
--- ----------------- ------------------------------------
c) Currency GBP
--- ----------------- ------------------------------------
d) Price(s) Director Exercise Volume
and volume(s) Price (p)
----------- ----------- --------
Liam Eves 5.0 136,364
----------- ----------- --------
--- -----------------
e) Aggregated
information
- Aggregated 136,364 options over Ordinary
volume Shares
- Exercise 5.0p
price
--- ----------------- ------------------------------------
f) Date of 15 January 2018
the transaction
--- ----------------- ------------------------------------
g) Place of London Stock Exchange, AIM
the transaction
--- ----------------- ------------------------------------
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive
Officer)
Graham Yeatman (Chief Financial
& Business Officer)
Media Enquiries +1 919 710 9658
Susan Flood (Head of Marketing)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Michael Burke
(Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster
Mitchell (UK) +44 203 727 1000
John Capodanno / Evan Smith
(US) +1 212 850 5705
Notes to Editors:
hVIVO plc ("hVIVO"), a specialty biopharma company with
discovery and clinical testing capabilities, is pioneering a
human-based analytical platform to accelerate drug discovery and
development in respiratory and infectious diseases. Leveraging
human disease models in flu, RSV and asthma exacerbation, the hVIVO
platform captures disease in motion, illuminating the entire
disease life cycle from healthy to sick and back to health. Based
in the UK, market leader hVIVO has conducted more than 50 clinical
studies, inoculated over 2500 volunteers and has three
first-in-class therapies currently in development with a growing
pre-clinical pipeline.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUVRVRWVAAAAR
(END) Dow Jones Newswires
January 16, 2018 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From May 2023 to May 2024